CVS Health stock surge on earnings beat

What happened: CVS Health (NYSE: CVS) stock surged on Wednesday, April 26, after the company reported earnings that surpassed $100 billion and raised its annual adjusted net income guidance. The positive results were driven by several initiatives, including a new program to facilitate access to GLP-1 medicines through its 9,000 pharmacies. Meanwhile, Eli Lilly's stock rebounded after CVS restored access to both Lilly and Novo Nordisk's GLP-1 drugs.

Market impact: The healthcare sector, particularly pharmacy benefit managers and drug retailers, saw a boost following CVS's strong earnings. The company's improved financial outlook and strategic initiatives, such as the GLP-1 access program, drove investor confidence. Lilly's stock also benefited from CVS's decision to maintain equal access to its and Novo Nordisk's GLP-1 drugs.

What to watch next: Investors should monitor CVS's upcoming earnings reports, scheduled for July 27, to assess the company's continued financial performance. Additionally, they should keep an eye on the technical levels of CVS's stock, as it challenges its all-time high around $95. Lastly, regulatory decisions regarding GLP-1 drugs and their accessibility could impact CVS's future growth and the broader healthcare sector.